CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Nov 2026 · 1 min read
In brief
In brief
This study identifies CD133-positive cells as a chemoresistant, myogenically primitive subpopulation within rhabdomyosarcoma cell lines that exhibit cancer stem cell characteristics. Despite resistance to conventional chemotherapy, these CD133+ cells demonstrate selective vulnerability to mutant oncolytic herpes simplex virus, suggesting a potential targeted therapeutic approach for treatment-resistant disease.
Written by the GCMD Library team from the article.
Statements in this article
Rhabdomyosarcoma is comprised of two major histological subtypes: embryonal (E-RMS) and alveolar (A-RMS).
Subsets of each rhabdomyosarcoma subtype demonstrate resistance to multimodal therapy leading to treatment failure.
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant.
CD133-positive rhabdomyosarcoma cells are sensitive to mutant herpes simplex virus.